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Purpose
There is limited data on radiotherapy (RT) for hepatocellular carcinoma (HCC) in patients
with Child-Pugh classification B (CP-B). This study aimed to evaluate the treatment outcomes
of fractionated conformal RT in HCC patients with CP-B.
Materials and Methods
We retrospectively reviewed the data of HCC patients with CP-B treated with RT between
2009 and 2014 at 13 institutions in Korea. HCC was diagnosed by the Korea guideline of
2009, and modern RT techniques were applied. Fraction size was  5 Gy and the biologically
effective dose (BED)  40 Gy10 (/=10 Gy). A total of 184 patients were included in this
study.
Results
Initial CP score was seven in 62.0% of patients, eight in 31.0%, and nine in 7.0%. Portal
vein tumor thrombosis was present in 66.3% of patients. The BED ranged from 40.4 to 89.6
Gy10 (median, 56.0 Gy10). After RT completion, 48.4% of patients underwent additional treat-
ment. The median overall survival (OS) was 9.4 months. The local progression-free survival
and OS rates at 1 year were 58.9% and 39.8%, respectively. In the multivariate analysis,
non-classic radiation-induced liver disease (RILD) (p < 0.001) and additional treatment (p
< 0.001) were the most significant prognostic factors of OS. Among 132 evaluable patients
without progressive disease, 19.7% experienced non-classic RILD. Normal liver volume was
the most predictive dosimetric parameter of non-classic RILD. 
Conclusion
Fractionated conformal RT showed favorable OS with a moderate risk non-classic RILD. The
individual radiotherapy for CP-B could be cautiously applied weighing the survival benefits
and the RILD risks.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies and the second leading cause of cancer-
related death in the world [1]. Because HCC usually deve-
lops in patients with underlying liver cirrhosis, the coexis-
tence of two life-threatening conditions of cancer itself and
cirrhosis complicates the prognosis [2]. Child-Pugh classifi-
cation (CP) is the most widely used system to assess the
severity of underlying liver cirrhosis. In HCC patients with
well-compensated liver function (CP class A, CP-A), the 
efficacy and safety of various treatment modalities according
to the tumor extent are well documented. However, in cases
of a borderline liver function (CP-B), liver cirrhosis further
limits the applicability of certain treatment modalities 
because some standard therapies are a strain on the patients
or can cause collateral damage to the non-cancerous liver tis-
sue, thereby potentially further aggravating liver dysfunc-
tion [3]. A recent review article suggested that the best
approach for treating HCC patients with CP-B would be to
assess the prognostic weight of the HCC burden in the indi-
vidual patient compared with that of cirrhosis severity and
to adapt eventual tumor treatment to the liver function for
tolerability and potential benefit [4]. 
Although radiotherapy (RT) was previously limited to
HCC treatment owing to the low tolerance dose of the whole
liver to RT [5], the developments in imaging and the intro-
duction of 3-dimensional conformal radiotherapy (3DCRT)
have enabled the delivery of conformal RT to the partial
liver. In addition, further development of RT techniques, 
including intensity-modulated radiotherapy (IMRT), and
stereotactic body radiotherapy (SBRT), have been expanded
the role of RT for HCC [6]. Hepatic toxicity after RT is 
defined as radiation-induced liver disease (RILD), which typ-
ically occurs between 2 weeks to 3 months after RT, and the
overall incidence has been reported to be 0%-20% [7,8]. Vir-
tually all prospective and retrospective studies have inclu-
ded patients with CP-A and CP-B only, and the most of those
with CP-B were classified as CP-B7 [9]. Culleton et al. [10]
retrospectively reported that 63% of patients had a decline
in CP score of  2 points after SBRT in HCC patients with CP-
B or -C. In contrast, in subgroup analyses of  20 patients
with CP-B in few studies, the incidence of RILD was 27%-
63%. This suggest that SBRT should be used with caution or
omitted for cases of severely impaired liver function.
Therefore, we performed a retrospective multi-institu-
tional study with a large cohort obtained from 13 institutions
of the Korean Radiation Oncology Group (KROG) to evalu-
ate the efficacy and toxicity of fractionated conformal RT for
HCC patients with CP-B.
Materials and Methods
1. Patient selection
We retrospectively reviewed the medical records of pati-
ents who received RT for HCC at 13 institutions of the
KROG. The inclusion criteria were as follows: (1) HCC was
diagnosed based on the Korean Liver Cancer Study Group
(KLCSG) and the National Cancer Center (NCC) practice
guideline of 2009 and was treated with RT between 2009 and
2014 [11]; (2) Eastern Cooperative Oncology Group perform-
ance score of 0-2; (3) CP-B; (4) treatment with modern RT
techniques such as 3DCRT or IMRT; and (5) fraction size  5
Gy and the biologically effective dose (BED)  40 Gy10 when
the / ratio was assumed to be 10 Gy. The exclusion criteria
were as follows: (1) huge HCC beyond 60% of the total liver
volume (TLV), for which RT was not feasible according to
the KLCSG and NCC practice guideline of 2009; (2) extrahep-
atic spread beyond the regional lymph nodes; (3) history of
previous RT to the liver; (4) history of additional RT for other
HCC in the liver within 3 months; and (5) history of malig-
nancies besides HCC within 5 years. A total of 184 patients
were included in this study.
2. Evaluation of hepatic toxicity
Patients underwent a physical examination, laboratory
tests, and computed tomography and/or magnetic reso-
nance imaging to assess hepatic function and evaluate the
tumor extent before RT as well as to assess hepatic toxicity
and the tumor response at follow-up visits. Hepatic toxicity
was categorized as classic and non-classic RILD. Classic
RILD included anicteric hepatomegaly, ascites, or elevated
alkaline phosphatase more than twice the upper limit of nor-
mal value. Non-classic RILD included elevation of liver
transaminases more than 5 times the upper limit of normal
level or a worsening of CP score of  2 points. We defined
the occurrence of non-classic RILD in the absence of docu-
mented progressive disease within 3 months after the end of
RT as significant toxicity. Therefore, we subsequently exclu-
ded these patients from the entire study population as shown
in Fig. 1 to minimize confounding factors. The remaining 132
patients were evaluated for hepatic toxicity.
For dosimetric analysis, the dose-volumetric values were
calculated from dose-volume histograms. The normal liver
volume (NLV) was defined as the TLV minus the gross
tumor volume in seven institutions and as the TLV minus
the planning target volume in six institutions. Doses deliv-
ered to specific volumes of the TLV and NLV were evalu-
ated. Due to variations in the fractionation schemes among
institutions, all doses were converted into the equivalent
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dose of 2 Gy per fraction (EQD2) using a linear-quadratic
model when the / ratio for the normal liver was assumed
to be 8 Gy (EQD2 with / ratio of 8 Gy=EQD28) [12]. This is
applied to calculate the mean dose of the TLV (DTLV_mean
EQD28) and NLV (DNLV_mean, EQD28), the percentage of the
TLV  5 Gy (TLV5Gy EQD28),  10 Gy (TLV10Gy EQD28),  15 Gy
(TLV15Gy EQD28),  20 Gy (TLV20Gy EQD28),  25 Gy (TLV25Gy
EQD28),  30 Gy (TLV30Gy EQD28),  35 Gy (TLV35Gy EQD28),
 40 Gy (TLV40Gy EQD28), the percentage of the NLV  5 Gy
(NLV5Gy EQD28),  10 Gy (NLV10Gy EQD28),  15 Gy (NLV15Gy
EQD28),  20 Gy (NLV20Gy EQD28),  25 Gy (NLV25Gy EQD28),
 30 Gy (NLV30Gy EQD28),  35 Gy (NLV35Gy EQD28), and 
 40 Gy (NLV40Gy EQD28).
3. Statistics
Local progression was defined as tumor growth or regrow-
th in any direction beyond that on pre-RT images of treated
lesions by the modified Response Evaluation Criteria in Solid
Tumor. Intrahepatic progression was defined as any progres-
sion within the liver. Local progression-free survival (LPFS),
intrahepatic progression-free survival (IHPFS), and overall
survival (OS) rates were estimated using the Kaplan-Meier
method from the date of start of RT. Patients were censored
at the date of death or at the date of last known follow-up,
whichever came first. Prognostic factors affecting OS were
analyzed using the Kaplan-Meier method for univariate
analysis. Multivariate analysis was performed using a Cox
proportional hazards model. A p-value < 0.05 was consid-
ered statistically significant.
To determine parameters affecting non-classic RILD in
evaluable patients, clinical parameters were analyzed as cat-
egorical or continuous variables, and dosimetric parameters
were analyzed as continuous variables. Univariate logistic
regression analysis was performed to compare clinical and
dosimetric parameters. In addition, a calculation of the area
under the curve (AUC) of receiver operating characteristics
(ROC) was used to determine the most predictive dosimetric
parameter of non-classic RILD. As the AUC approximates
1.0, the parameter becomes more predictive of non-classic
RILD. All calculations were performed using the Statistical
Package for the Social Sciences software (SPSS ver. 20.0, IBM
Corp., Armonk, NY).
4. Ethical statement
The current study was approved by the KROG (KROG 
16-05) and the institutional review board of each participat-
ing institution (K-2016-2830). Written informed consent was
waived due to the retrospective nature of the study.
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184 Patients
132 Patients were included in the analysis of hepatic toxicity
Intrahepatic
progression (+)
n=24
Intrahepatic
progression (–)
n=4
Hepatic toxicity
(+)
Death
within 3 months
Survival
over 3 months
Hepatic toxicity
(–)
Hepatic toxicity
(+)
Hepatic toxicity
(–)
Intrahepatic
progression (+)
n=6
Intrahepatic
progression (–) and
unknown death
n=2
Interruption of
follow-up study
during 1st 
3 months after RT 
n=5
Intrahepatic
progression (+)
n=15
Intrahepatic
progression (–)
n=22
n=106
Fig. 1. Flowchart of evaluable patients’ recruitment process for toxicity analysis.
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Results
1. Patients’ characteristics
Patients’ characteristics at baseline are summarized in
Table 1. Of 184 patients, the median age was 58 years. Viral-
associated hepatitis due to hepatitis B or C virus was pre-
sented in 87.0% of patients. CP score was seven in 114 pati-
ents (62.0%), eight in 57 patients (31.0%), and nine in 13 pati-
ents (7.0%). The median tumor size was 5.4 cm. A single 
lesion was presented in 45.1% and portal vein tumor throm-
bosis (PVTT) was present in 66.3%. One hundred five pati-
ents (57.1%) had liver-directed therapy with 1-18 interven-
tions (median, 2) before RT; 80.0% received transarterial
chemoembolization (TACE). Combined treatment, defined
as a treatment administered within 4 weeks of the start or
end of RT, was conducted in 114 patients (62.0%); the most
common modality was TACE in 81 patients, followed by
transcatheter arterial chemotherapy infusion (TACI) in 32 
patients. Most patients (87.5%) received 3DCRT, and 53.8%
of patients received curative-intent RT, including all viable
tumors. The total RT dose ranged from 31.5 to 64.0 Gy 
(median, 44.0 Gy), and the fraction size ranged from 1.5 to
5.0 Gy (median, 2.5 Gy). Eighty-nine patients (48.4%) under-
went additional treatment after RT with 1-9 interventions
(median, 2), including TACE (67 patients), TACI (15 pati-
ents), sorafenib (13 patients), systemic chemotherapy (6 pati-
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Table 1. Patients’ characteristics at baseline
(Continued)
Characteristic No. of patients (%)
Age, median (range, yr) 58 (39-85)
Sex
Male 158 (85.9)
Female 26 (14.1)
ECOG score
0 54 (29.3)
1 80 (43.5)
2 50 (27.2)
Hepatitis
No 11 (6.0)
HBV 135 (73.4)
HCV 25 (13.6)
Alcoholic 13 (7.0)
Initial CP score
7 114 (62.0)
8 57 (31.0)
9 13 (7.0)
Tumor size, median (range, cm) 5.4 (1-21)
No. of tumors
1 83 (45.1)
2-3 54 (29.4)
4-9 23 (12.5)
 10 24 (13.0)
Tumor location
One lobe 131 (71.2)
Both lobes 53 (28.8)
Bile duct invasion
No 150 (81.5)
Yes 34 (18.5)
PVTT
No 62 (33.7)
Yes 122 (66.3)
Main PVTT 54 (44.3) 
Branched PVTT 68 (55.7)
mUICC_T 
1 10 (5.4)
2 21 (11.4)
3 61 (33.2)
4 92 (50.0)
mUICC_N
0 158 (85.9)
1 26 (14.1)
Previous liver-directed therapy
No 79 (42.9)
Yes 105 (57.1)
Combined treatment
No 70 (38.0)
Yes 114 (62.0)
Table 1. Continued
ECOG, Eastern Cooperative Oncology Group; HBV, hep-
atitis B virus; HCV, hepatitis C virus; CP, Child-Pugh;
PVTT, portal vein tumor thrombosis; mUICC, the modi-
fied International Union Against Cancer stage; T, tumor;
N, lymph nodes; BED, biologically effective dose when the
/ ratio was assumed to be 10 Gy; AFP, -fetoprotein.
a)The cease of RT was due to patients’ refusal (n=2), decrea-
sed general performance (n=2); aggravation of hyperbi-
lirubinemia (n=1).
Characteristic No. of patients (%)
Fraction size, median (range, Gy) 2.5 (1.5-5)
BED, median (range, Gy10) 56.0 (40.4-89.6)
RT completion
Yes 179 (97.3)
No 5 (2.7)a)
AFP, median (range, IU/mL) 242.7 (0.7-1136990)
Additional treatment
No 95 (51.6)
Yes 89 (48.4)
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Fig. 2.  Local progression-free survival (LPFS) (A), intrahepatic progression-free survival (IPFS) (B), and overall survival
(OS) (C) curves.
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Fig. 3.  Hepatic toxicity defined as classic and non-classic radiation-induced liver disease (RILD) within 3 months after the
end of radiotherapy in 184 patients (entire cohort, A) and in 132 patients (evaluable cohort, B). CP, Child-Pugh classifica-
tion.
Non-classic RILD (66 patients, 35.9%)
Classic RILD (22 patients, 12.0%)
A
44 5
9
1
14
5 2
Non-classic RILD (26 patients, 19.7%)
Classic RILD (16 patients, 12.1%)
B
Liver transaminases
≥ 5 times
15 2
4
0
11
4 1
Liver transaminases
≥ 5 times
CP score    ≥ 2 points CP score    ≥ 2 points
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Table 2.  Univariate analysis and multivariate analysis for prognostic factors affecting OS
Factor No. of  1-Year Median UVA MVA MVApatients OS (%) OS (mo) p-value HR (95% CI) p-value
Age (yr)
 60 107 30.8 8.3 0.154 0.722 0.104
> 60 77 51.3 12.2 (0.487-1.069)
Sex
Male 158 35.8 9.1 0.055 1.174 0.622
Female 26 60.6 13.4 (0.621-2.219)
ECOG score
0-1 134 40.2 9.4 0.817 - -
2 50 37.2 9.7
Hepatitis
No 10 57.1 20.7 0.020 Reference 0.011
HBV/HCV 160 40.0 9.5 1.970 0.125
(0.829-4.683)
Alcoholic 14 19.0 5.3 4.559 0.005
(1.570-13.235)
Initial CP score
7 114 43.2 10.7 0.381 - -
8 57 35.5 9.1
9 13 23.1 5.6
Tumor size (cm)
 5 85 48.7 11.1 0.019 - -
> 5 99 31.4 8.0
No. of tumors
1-3 137 43.6 10.1 0.014 - -
 4 47 26.7 8.0
Tumor location
One lobe 131 42.1 10.1 0.052 - -
Both lobes 53 32.6 8.2
PVTT
No 62 55.1 13.2 < 0.001 1.022 0.928
Yes 122 31.6 8.0 (0.636-1.643)
mUICC_T
1, 2 31 72.7 24.1 < 0.001 3.277 0.002
3, 4 153 32.5 8.3 (1.546-6.944)
mUICC_N
0 158 41.8 10.0 0.031 1.355 0.242
1 26 22.8 6.4 (0.815-2.254)
Initial AFP (IU/mL)
 200 87 47.1 11.1 0.003 1.875 0.005
> 200 92 29.2 8.0 (1.207-2.911)
RT aima)
Curative 99 43.2 10.1 0.044 0.876 0.486
Palliative 85 34.8 8.3 (0.604-1.271)
BED (Gy10)
 53 75 31.4 8.3 0.029 0.946 0.760
> 53 109 45.1 10.1 (0.664-1.349)
AFP responseb)
Yes 79 44.4 9.8 0.012 0.593 0.013
No 81 24.2 6.6 (0.393-0.894)
(Continued to the next page)
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ents), RT (5 patients), liver transplantation (5 patients), and
radiofrequency ablation (1 patient). 
2. Outcomes 
The median follow-up period was 7.3 months (range, 0.7
to 67.7 months). The median OS was 9.4 months, and the 
actuarial 6-month and 1-year LPFS, IHPFS, and OS rates
were 78.0% and 58.9%, 43.1% and 22.1%, and 70.8% and
39.8%, respectively (Fig. 2). Hepatic toxicity occurred in 80
patients (43.5%) within 3 months after the end of RT; 22 pati-
ents (12.0%) experienced classic RILD and 66 (35.9%) experi-
enced non-classic RILD (Fig. 3A). After the occurrence of
classic RILD, 15 patients (68.2%) recovered their own liver
function: three patients (13.6%) suffered from persistent 
hepatic dysfunction; four patients (18.2%) experienced intra-
hepatic progression and were impossible to assess. Among
patients with non-classic RILD, 10 patients (15.2%) recovered
their own liver function: 17 patients (25.8%) suffered from
persistent hepatic dysfunction; 39 patients (59.0%) experi-
enced intrahepatic progression and were impossible to assess.
The results of the univariate and multivariate analysis for
prognostic factors affecting OS are summarized in Table 2.
In multivariate analysis, non-classic RILD (hazard ratio [HR],
2.674; 95% confidence interval [CI], 1.826 to 3.916; p < 0.001)
and additional treatment (HR, 2.159; 95% CI, 1.479 to 3.152;
p < 0.001) were the most significant factors affecting OS.
3. Predictors for non-classic RILD
In 132 evaluable patients described in Fig. 1, hepatic toxi-
city occurred in 37 patients (28.0%) within 3 months after the
end of RT. The characteristics are listed in S1 Table. Classic
RILD occurred in 16 patients (12.1%) and non-classic RILD
occurred in 26 patients (19.7%); among patients with non-
classic RILD, 23 patients experienced a worsening of CP
score by  2 points (Fig. 3B). Univariate logistic regression
analysis was conducted to determine clinical and dosimetric
parameters affecting non-classic RILD, which was the most
significant prognostic factor for OS in both univariate and
multivariate analysis. Of the clinical parameters, only the RT
technique was associated with the risk of non-classic RILD
(p=0.007) (S2 Table). Of the dosimetric parameters, NLV,
DTLV_mean EQD28, TLV15Gy EQD28, TLV20Gy EQD28, TLV35Gy
EQD28, and TLV40Gy EQD28 were associated with the risk of
non-classic RILD (Table 3). NLV was the most predictive
dosimetric parameter based on compared values from the
AUC of ROC. 
Discussion
RT is mostly administered to HCC patients with CP-A, and
only a few studies have examined the efficacy of RT for 
CP-B [13,14]. Culleton et al. [10] reported a median OS of 7.9
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Table 2.  Continued
Factor No. of  1-Year Median UVA MVA MVApatients OS (%) OS (mo) p-value HR (95% CI) p-value
Classic RILD
No 162 41.2 9.7 0.582 - -
Yes 22 27.3 7.7
Non-classic RILD
No 118 51.3 12.2 < 0.001 2.674 < 0.001
Yes 66 17.2 5.1 (1.826-3.916)
Additional treatment
No 95 27.0 7.0 0.001 2.159 < 0.001
Yes 89 51.7 12.2 (1.479-3.152)
OS, overall survival; UVA, univariate analysis; MVA, multivariate analysis; HR, hazard ratio; CI, confidence interval; ECOG,
Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; CP, Child-Pugh; PVTT, portal vein
tumor thrombosis; mUICC, the modified International Union Against Cancer stage; T, tumor; N, lymph nodes; AFP, -feto-
protein; RT, radiotherapy; BED, biologically effective dose when the / ratio was assumed to be 10 Gy; RILD, radiation-
induced liver disease. a)Curative intent means that RT field cover all viable tumors; palliative intent means that RT field
cover a part of viable tumors, b)Defined as AFP level reduction of > 20% from the initial level at 1 months after completion
of RT in 160 patients who check follow-up AFP level.
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months in CP-B or -C patients treated with SBRT for HCC:
9.9 months in CP-B7 patients and 2.8 months in CP  8. In
contrast, Nabavizadeh et al. [15] reported a superior survival
rate of 11.8 months after SBRT or accelerated hypofraction-
ated RT (AHRT). The authors suggested that favorable pati-
ents’ characteristics, such as a unifocal tumor, smaller tumor
size, and PVTT in 10% of patients, may have contributed to
the improvement in OS. Our fractionated conformal RT
showed a comparable survival of 9.4 months, despite the 
inclusion of patients with unfavorable characteristics, e.g.,
T3/T4, multiple HCCs, large tumor size, and PVTT. How-
ever, local control (LC) was suboptimal compared with SBRT
studies with a 1-year LPFS rate of 58.9%. Ohri et al. [16]
found that there was no clear evidence for a dose-response
relationship with a BED of 60-180 Gy10 for SBRT to primary
liver tumors and suggested that SBRT with 60-72 Gy10 was a
reasonable fractionation scheme, with a 2-year LPFS of 90%.
In addition, Nabavizadeh et al. [15] showed statistically sig-
nificant superior LC rates for SBRT group compared to
AHRT group, with a 2-year LC rate of 94% vs. 65%. How-
ever, a nationwide survey in Korea reported that SBRT was
selectively used for small-sized HCC with CP-A and that RT
was mainly considered for advanced HCC and combined
treatment using fractionated conformal RT was common
clinical practice patterns [17,18]. In addition, HCC occurs in
developing countries, especially in Asia where there are lim-
ited health resources. Therefore, we suggest that fractionated
conformal RT as a practical alternative to SBRT, although fur-
ther prospective studies to improve its efficacy are required.
The incidence of RILD after RT is higher in HCC patients
with CP-B than with CP-A. An SBRT study for HCC in 29 
patients with CP-B or -C reported the highest toxicity rate of
63%, resulting in a worsening of CP score by  2 points after
a median dose of 30 Gy in six fractions [10]. They suggested
SBRT for selected CP-B7 patients but did not recommend it
for patients with CP  8 outside of studies. Another study
using SBRT (50 Gy in 5 fractions) or AHRT (45 Gy in 18 frac-
tions) presented a worsening of CP score by  2 points in 27
out of 95 patients (28%) with CP-A or -B7 and in 18 out of 51
patients (35%) with CP-B8, -B9, or -C [15]. As the true toler-
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Table 3.  Univariate analysis for dosimetric parameters affecting non-classic radiation-induced liver disease
ROC, receiver operator characteristics; AUC, area under the curve; GTV, gross tumor volume; TLV, total liver volume; NLV,
normal liver volume, which was defined as the total liver volume minus GTV in seven institutions and as the TLV minus
the planning target volume in six institutions; EQD2, equivalent dose of 2 Gy per fraction. a)Due to variations in the fraction-
ation, all doses converted into the EQD2 using linear-quadratic model when the / ratio for the normal liver was assumed
to be 8 Gy, b)The percentage of the TLV  X Gy, c)The percentage of the NLV  X Gy.
Parameter Mean±standard deviation p-value ROC AUC
GTV (mL) 287.7±585.7 0.211 0.666
TLV (mL) 1,555.8±758.7 0.311 0.571
NLV (mL) 1,184.4±442.2 0.013 0.694
DTLV_mean EQD28 (Gy)a) 18.1±8.8 0.041 0.593
TLV5Gy EQD28 (%)b) 71.8±17.3 0.120 0.582
TLV10Gy EQD28 (%) 58.9±18.3 0.082 0.607
TLV15Gy EQD28 (%) 50.0±18.9 0.023 0.644
TLV20Gy EQD28 (%) 43.2±19.6 0.019 0.648
TLV25Gy EQD28 (%) 37.6±19.6 0.051 0.618
TLV30Gy EQD28 (%) 32.7±19.9 0.051 0.594
TLV35Gy EQD28 (%) 28.5±19.3 0.039 0.595
TLV40Gy EQD28 (%) 21.8±19.5 0.003 0.635
DNLV_mean EQD28 (Gy) 13.9±5.4 0.794 0.508
NLV5Gy EQD28 (%)c) 68.7±17.4 0.203 0.582
NLV10Gy EQD28 (%) 53.0±16.2 0.373 0.560
NLV15Gy EQD28 (%) 42.0±15.2 0.190 0.592
NLV20Gy EQD28 (%) 34.1±14.4 0.143 0.606
NLV25Gy EQD28 (%) 27.7±13.4 0.495 0.551
NLV30Gy EQD28 (%) 22.4±12.4 0.470 0.551
NLV35Gy EQD28 (%) 17.9±11.3 0.205 0.577
NLV40Gy EQD28 (%) 12.1±10.8 0.057 0.591
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ability of RT in patients with CP-B or -C is unknown, the 
authors proposed further prospective trials. In a hypofrac-
tionated 3DCRT study using 40-60 Gy with a fraction size of
4-8 Gy, classic or non-classic RILD occurred in 12 out of 20
patients (60%) with CP-B, compared to 7 out of 108 (6%) with
CP-A [19]. They stated that CP-B patients did not tolerate the
hypofractionated RT. On the other hand, conventional frac-
tionated RT may be more tolerable. A 3DCRT study using 66
Gy in 33 fractions reported that three out of 11 patients (27%)
with CP-B experienced grade 4 hepatic toxicity [20]. How-
ever, as all of these patients had grade 3 abnormalities before
RT, the correlation of toxicity to the RT is not entirely clear.
In the current study, non-classic RILD was observed in 19.7%
of 132 evaluable patients after fractionated conformal RT
with a median fraction size of 2.5 Gy. Considering that nor-
mal tissue toxicity is more greatly impacted by fraction size
in terms of radiobiology, we suggested the use of fraction-
ated conformal RT for HCC in CP-B patients to minimize tox-
icity [21]. Because most patients were CP-B7 or -B8, however,
the safety of fractionated conformal RT for patients with CP-
B9 has still undetermined and we should treat them with
considerable caution. 
To the best of our knowledge, this is the largest study in
published data evaluating predictors for non-classic RILD in
HCC patients with CP-B treated with fractionated conformal
RT. Although several dosimetric parameters were statisti-
cally significant in univariate analysis, we were unable to
identify the definite dosimetric constraints because values
from the AUC of ROC were suboptimal for the selections of
cut-off points. Other recent studies have attempted to obtain
the definitive constraints in CP-B patients but did not suc-
ceed [15,22]. There are some practical limitations to identify
dosimetric predictors. Firstly, our study applied various
NLV definitions according to different institutions because
plan data which was already approved before RT were ret-
rospectively reviewed. In addition, we defined the / ratio
of the normal liver as 8 to compare different fractionation
schedules among institutions, based on the Korean data 
reflecting similarities in the underlying disease, applied frac-
tion schemes, and combined modalities [12]. However, the
/ ratio of the normal liver is still unknown, and it ranges
between 2, 2.5, 3, 8, and 10 [23-26]. These variances may con-
found the importance of dosimetric parameters. Secondly,
RT for CP-B patients have a higher probability of RILD, 
especially non-classic RILD: however, the underlying pathol-
ogy of non-classic RILD remains unclear [7]. Thirdly, CP-B,
as a preexisting liver dysfunction, has the intrinsic morbidity.
In a randomized trial in advanced HCC patients, the rate of
serious adverse events among the placebo group because of
progression of cirrhosis or HCC was 52% [27]. However, it
is impossible to distinguish between RILD and the natural
progression of underlying cirrhosis in a clinical setting.
Therefore, further prospective studies are required to mini-
mize confounding factors and obtain practical constraints. 
There were some limitations to the current study. Firstly,
there was the interinstitutional heterogeneity of HCC man-
agement, because the KLCSG and NCC practice guideline-
recommended RT only for HCC patients with well-preser-
ved liver function (CP-A or upper B) and could not encom-
pass all possible clinical situations. However, a certain degree
of heterogeneity among institutions mirrors clinical practice
in the real world, providing results more representative of
what can be achieved in everyday practice than findings
from an ideal setting [28]. This is particularly important for
HCC as a large gap exists between applied practice and evi-
dence-based treatment, making our multicenter study more
representative [29]. Secondly, as we only included patients
who received RT  40 Gy10, patients who could not complete
RT or decreased the total dose due to acute toxicities or other
possible causes would be excluded. This may overestimate
the efficacy of RT for patients with CP-B. Thirdly, this study
was a retrospective analysis. Therefore, selection and con-
founding biases may have occurred, and the rates of hepatic
toxicity may have been underestimated. To minimize the 
effect of these limitations, we only analyzed cases with com-
pleted follow-up during the 3 months after RT without dis-
ease progression.
In conclusions, fractionated conformal RT showed favor-
able OS when compared to other published studies in HCC
patients with CP-B and a moderate risk of non-classic RILD
even if it was lower than that reported in previous SBRT
studies. The individual RT for CP-B could be cautiously 
applied considering that non-classic RILD was the most sig-
nificant factor affecting OS. In Korea, IMRT and proton beam
therapy have been approved by the National Health Insur-
ance Service from 2015. The application of these advanced
RT techniques using fractionated RT might provide some 
answers to improve the efficacy of RT without increasing the
incidence of non-classic RILD for HCC patients with CP-B.
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